Video

Cell Therapies May Help Overcome Drug Resistance in Patients With Mantle Cell Lymphoma

Author(s):

Dr. Michael Wang
Conference|ASCO Annual Meeting

Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.

Drug resistance is one major roadblock in cancer researchers’ way of improving patient outcomes in mantle cell lymphoma (MCL) treatment, according to Dr. Luhua (Michael) Wang.

However, promising developments in the treatment of MCL and other B-cell lymphomas could help patients overcome drug resistance and live longer lives.

“To overcome drug resistance, we’ve had three major technology achievements in the past few years. In the past, we always used chemotherapy,” said Wang, who is a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, explaining that the rapid advancements included targeted therapies, immunotherapies and cell therapies.

At the 2019 American Society of Clinical Oncology Annual (ASCO) Meeting, Wang discussed study findings and the technological advances in B-cell lymphoma treatment space that provide hope for patients with MCL of overcoming drug resistance and potentially live longer.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Image of a lymphoma cell.
November 19th 2024

Columvi Shows High Response Rates and Safety in R/R Mantle Cell Lymphoma

Spencer Feldman
Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of radiation targeting cancer cells.
November 5th 2024

Common Prostate Cancer Radiation Questions Answered

Alex Biese
Expert answers to patients’ questions were offered as part of the CURE® Educated Patient® Prostate Cancer Summit.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of PSA test.
October 21st 2024

Rise in PSA Levels May Predict Treatment Response in Prostate Cancer

Spencer Feldman
The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment.
Image of doctor consulting man.
October 18th 2024

Focal Therapy May Reduce Side Effects, Improve Quality of Life in Prostate Cancer

Darlene Dobkowski, MA
With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary incontinence and erectile dysfunction, an expert said.